DNMT1 and cancer: While cancer epigenetics approaches have been successful and DNMT and HDAC inhibitors are clinically advanced and have been approved by the FDA, underlying mechanisms of epigenetic drugs and a deeper understanding of signaling processes could further enlighten epigenetic therapy.